09:45 AM EDT, 07/16/2025 (MT Newswires) -- Citius Oncology ( CTOR ) said Wednesday that it priced its "reasonable best-efforts" public offering of about 6.8 million common shares and warrants to purchase common shares at $1.32 per share, for total proceeds of about $9 million.

The company said the warrants are immediately exercisable for $1.32 per share and will expire five years from issuance.

Citius said net proceeds will be used to support the commercialization of Lymphir and for general corporate purposes. The offering is expected to close on or about Thursday, the company said.

Shares of Citius Oncology ( CTOR ) were down more than 7% in early Wednesday trading.

Price: 1.42, Change: -0.12, Percent Change: -7.79